

Remote Viewing Analysis Report

Completed: 2026-09-10T03:48:51.655357+00:00

Unblinded: 2026-09-10T03:48:58.753370+00:00

Experiment design

90 frozen primary trials; 30 physical targets, each represented once in Campbell, Placebo, and Neutral. Each target used the same four decoys across conditions. Each trial had independently randomized photograph order. All trials were mixed into one queue, with at least 15 intervening trials between repetitions of a true target. Every ranking was locked before explicit unblinding. Specificity never affects the primary rank.

Protocol deviations and audit

- Seven accidental duplicates were excluded and their intended slots were replaced before scoring, as declared in the frozen dataset.

PRIMARY / PREREGISTERED-LIKE OUTCOMES

Primary endpoint: true target ranked first, tested one-sided against $p = 0.20$. Supplemental two-sided binomial p-values and two-sided 95% Clopper–Pearson exact intervals are shown. Classification here does not itself establish preregistration.

condition	hits	hit rate	chance	one sided p	two sided p	exact 95 percent CI
Campbell	4 / 30	13.3%	20%	0.877289	0.494443	3.8% – 30.7%
Placebo	5 / 30	16.7%	20%	0.744767	0.820543	5.6% – 34.7%
Neutral	10 / 30	33.3%	20%	0.0610871	0.105266	17.3% – 52.8%

Supplemental rank summaries

Lower mean target rank is better. Rank columns show trial counts.

condition	mean rank	median rank	rank 1	rank 2	rank 3	rank 4	rank 5
Campbell	2.96667	3	4	9	6	6	5
Placebo	3.13333	3	5	7	5	5	8
Neutral	2.6	2	10	6	5	4	5

Paired condition comparisons

Targets are paired across conditions. Exact two-sided McNemar tests condition on discordant pairs; no discordances yields $p = 1$. Rank comparisons use two-sided Wilcoxon signed-rank tests, omitting zeros with tie and continuity corrections in a normal approximation. These paired comparisons supplement the primary endpoint; rank comparisons are exploratory. P-values are not multiplicity-adjusted.

Campbell vs Neutral

paired 2x2		second condition hit		second condition miss	
First condition: hit		1		3	
First condition: miss		9		17	
exact McNemar p	Wilcoxon statistic	Wilcoxon p	median rank difference	mean rank difference	
0.145996	170.5	0.461184	1	0.366667	

Campbell rank minus Neutral rank; negative favors Campbell. Neutral has lower mean rank

Campbell vs Placebo

paired 2x2		second condition hit		second condition miss	
First condition: hit		2		2	
First condition: miss		3		23	

exact McNemar p	Wilcoxon statistic	Wilcoxon p	median rank difference	mean rank difference
1	120.5	0.600684	0	-0.166667

Campbell rank minus Placebo rank; negative favors Campbell. Campbell has lower mean rank

Placebo vs Neutral


paired 2x2		second condition hit		second condition miss	
First condition: hit		3		2	
First condition: miss		7		18	
exact McNemar p	Wilcoxon statistic	Wilcoxon p	median rank difference	mean rank difference	
0.179688	100	0.15122	0.5	0.533333	

Placebo rank minus Neutral rank; negative favors Placebo. Neutral has lower mean rank


Overall Friedman test — exploratory

statistic	p value	method
2.90385	0.23412	Tie-corrected Friedman chi-square approximation; paired by physical target, df=2.


Plots




Hit rate by condition, with 95% exact binomial confidence intervals




True-target rank distribution by condition



Mean target rank by condition



Trial position within planned session performance (exploratory)



Planned session performance (exploratory)

EXPLORATORY OUTCOMES

Specificity

condition				mean specificity
Campbell				1.86667
Placebo				1.86667
Neutral				1.7
group	n	rho	p value	note
overall	90	-0.00895889	0.933211	Exploratory Spearman correlation; p-value is asymptotic, with repeated targets not modeled. Negative rho associates higher scores with better (lower) ranks.
Campbell	30	-0.121108	0.523797	Exploratory Spearman correlation; p-value is asymptotic, with repeated targets not modeled. Negative rho associates higher scores with better (lower) ranks.
Placebo	30	-0.132985	0.483578	Exploratory Spearman correlation; p-value is asymptotic, with repeated targets not modeled. Negative rho associates

group	n	rho	p value	note
				higher scores with better (lower) ranks.
Neutral	30	0.130906	0.490501	Exploratory Spearman correlation; p-value is asymptotic, with repeated targets not modeled. Negative rho associates higher scores with better (lower) ranks.

Planned sessions

group	condition	n	rank1 hits	hit percentage	mean true target rank
1	Campbell	10	2	20	3
1	Placebo	10	1	10	3.3
1	Neutral	10	4	40	2.4
2	Campbell	10	1	10	2.7
2	Placebo	10	1	10	3.2
2	Neutral	10	2	20	2.7
3	Campbell	10	1	10	3.2
3	Placebo	10	3	30	2.9
3	Neutral	10	4	40	2.7

Trial position within planned session

group	condition	n	rank1 hits	hit percentage	mean true target rank
1	Campbell	3	2	66.6667	1.33333
1	Placebo	3	1	33.3333	2.66667
1	Neutral	3	1	33.3333	2
2	Campbell	3	0	0	2.33333
2	Placebo	3	1	33.3333	2.33333

group	condition	n	rank1 hits	hit percentage	mean true target rank
2	Neutral	3	1	33.3333	3
3	Campbell	3	0	0	4
3	Placebo	3	0	0	3.33333
3	Neutral	3	1	33.3333	2.66667
4	Campbell	3	1	33.3333	2
4	Placebo	3	3	100	1
4	Neutral	3	1	33.3333	3
5	Campbell	3	0	0	3.33333
5	Placebo	3	0	0	2.33333
5	Neutral	3	1	33.3333	2.33333
6	Campbell	3	0	0	2.66667
6	Placebo	3	0	0	4.66667
6	Neutral	3	0	0	3
7	Campbell	3	0	0	3.66667
7	Placebo	3	0	0	3
7	Neutral	3	2	66.6667	1.66667
8	Campbell	3	1	33.3333	3.33333
8	Placebo	3	0	0	3.66667
8	Neutral	3	1	33.3333	3.33333
9	Campbell	3	0	0	4
9	Placebo	3	0	0	4.33333

group	condition	n	rank1 hits	hit percentage	mean true target rank
9	Neutral	3	1	33.3333	1.66667
10	Campbell	3	0	0	3
10	Placebo	3	0	0	4
10	Neutral	3	1	33.3333	3.33333

Original versus correction replacements

group	condition	n	rank1 hits	hit percentage	mean true target rank
correction_replacement	Campbell	2	0	0	3.5
correction_replacement	Placebo	3	1	33.3333	2.66667
correction_replacement	Neutral	2	0	0	4.5
original	Campbell	28	4	14.2857	2.92857
original	Placebo	27	4	14.8148	3.18519
original	Neutral	28	10	35.7143	2.46429

Per-target ranks in all conditions

target id	Campbell	Placebo	Neutral
22MX-UQCV	4	5	3
3M4D-D6QK	4	2	2
5HPZ-G2ZS	4	3	2
77RZ-55NU	4	4	3
8KZM-KVM4	3	5	1
9EXL-JPCW	2	3	1
9HVR-79NR	2	2	5

target id	Campbell	Placebo	Neutral
9PA6-TYLT	5	1	2
AF4D-NG43	2	5	5
CE9E-ZRN2	5	5	1
D2T2-HUYC	5	2	3
G5MQ-43Y7	1	1	1
HFN9-DPRM	3	3	1
J5G7-MUNE	4	3	4
K39X-PE6Y	2	3	5
M3JW-WM39	1	5	4
MG87-TP8T	2	4	5
MPEN-XAFC	1	1	2
P5NN-D5ET	3	4	2
P7WX-4BZH	2	5	3
Q7MA-MHXY	3	2	1
R6XA-BAZH	3	2	1
RLA2-6WFM	2	2	5
S7ZX-RAK2	3	5	2
SJCJ-RD7E	5	2	4
SPY2-GRWE	5	1	1
UFZA-FKVH	4	5	1
W4WC-SV3T	1	4	4

target id	Campbell	Placebo	Neutral
WHCS-R6CC	2	1	1
ZNMH-4DZW	2	4	3

AI confidence

note
Skipped: no reliably parsed confidence score with an explicit numeric scale.

Interpretation cautions

- Above-chance performance would indicate an unexpected association between blinded AI descriptions and concealed targets under this protocol.
- It would NOT by itself establish the mechanism.
- It would NOT by itself prove AI consciousness.
- It would NOT by itself prove Thomas Campbell's larger consciousness model.
- Replication under stronger blinding would be required.
- The seven correction trials were created before scoring after accidental duplicate target identifiers were identified.
- Those seven accidental duplicate trials were excluded prior to target scoring and the correction trials replaced their intended slots.
- Outcome categories were specified when this scoring tool was built. This is not a claim of independently timestamped preregistration.
- P-values are unadjusted for multiple comparisons. Repeated descriptions and candidate sets can introduce dependence; the binomial model assumes independent trials within each condition.
- Pairing addresses repeated physical targets across conditions but does not establish causal effects or remove all sources of bias.
- Decoy sampling is random within target and is not balanced globally. Repeated image sets can be recognizable to a judge.
- Specificity and other exploratory analyses are subjective or post hoc and should not be overinterpreted.

Per-trial results

scoring order	condition	target id	planned session	trial position	source type	true target rank	top1 hit	speci
1	Neutral	WHCS-R6CC	1	4	original	1	1	1
2	Campbell	22MX-UQCV	1	5	original	4	0	2
3	Placebo	P7WX-4BZH	2	1	original	5	0	0
4	Neutral	SPY2-GRWE	2	10	original	1	1	1
5	Neutral	SJCJ-RD7E	1	10	original	4	0	2
6	Placebo	D2T2-HUYC	2	8	original	2	0	0
7	Campbell	Q7MA-MHXY	3	5	original	3	0	2
8	Neutral	9HVR-79NR	3	10	original	5	0	2
9	Neutral	HFN9-DPRM	3	9	original	1	1	0
10	Campbell	J5G7-MUNE	1	8	original	4	0	1
11	Campbell	R6XA-BAZH	2	5	original	3	0	0
12	Placebo	P5NN-D5ET	1	7	original	4	0	1
13	Placebo	9EXL-JPCW	2	5	original	3	0	2

scoring order	condition	target id	planned session	trial position	source type	true target rank	top1 hit	speci
14	Neutral	K39X-PE6Y	2	3	original	5	0	2
15	Campbell	77RZ-55NU	3	9	original	4	0	1
16	Placebo	M3JW-WM39	1	8	original	5	0	2
17	Placebo	W4WC-SV3T	3	3	original	4	0	3
18	Campbell	UFZA-FKVH	1	10	original	4	0	1
19	Campbell	5HPZ-G2ZS	2	7	original	4	0	2
20	Neutral	22MX-UQCV	2	2	original	3	0	2
21	Placebo	ZNMH-4DZW	1	2	original	4	0	1
22	Campbell	8KZM-KVM4	2	10	original	3	0	2
23	Campbell	AF4D-NG43	3	7	original	2	0	2
24	Placebo	G5MQ-43Y7	2	4	original	1	1	1
25	Placebo	CE9E-ZRN2	3	6	original	5	0	2
26	Placebo	9PA6-TYLT	1	4	correction_replacement	1	1	2

scoring order	condition	target id	planned session	trial position	source type	true target rank	top1 hit	speci
27	Placebo	S7ZX-RAK2	1	6	original	5	0	2
28	Neutral	P7WX-4BZH	1	7	original	3	0	2
29	Neutral	RLA2-6WFM	1	2	original	5	0	2
30	Neutral	9EXL-JPCW	2	7	original	1	1	2
31	Placebo	R6XA-BAZH	1	5	original	2	0	2
32	Placebo	SPY2-GRWE	3	2	original	1	1	2
33	Campbell	D2T2-HUYC	1	7	original	5	0	2
34	Placebo	MG87-TP8T	2	6	original	4	0	2
35	Placebo	3M4D-D6QK	3	5	original	2	0	3
36	Placebo	UFZA-FKVH	2	9	original	5	0	2
37	Campbell	MPEN-XAFC	1	1	original	1	1	3
38	Campbell	M3JW-WM39	3	1	original	1	1	2
39	Placebo	5HPZ-G2ZS	3	9	original	3	0	2

scoring order	condition	target id	planned session	trial position	source type	true target rank	top1 hit	speci
40	Campbell	9HVR-79NR	2	2	original	2	0	3
41	Neutral	P5NN-D5ET	2	1	original	2	0	2
42	Campbell	WHCS-R6CC	1	6	original	2	0	2
43	Campbell	W4WC-SV3T	2	8	original	1	1	2
44	Placebo	K39X-PE6Y	1	3	original	3	0	3
45	Placebo	SJCJ-RD7E	2	7	original	2	0	2
46	Campbell	9EXL-JPCW	2	1	original	2	0	1
47	Campbell	CE9E-ZRN2	3	8	correction_replacement	5	0	2
48	Campbell	ZNMH-4DZW	2	4	original	2	0	2
49	Neutral	AF4D-NG43	2	8	correction_replacement	5	0	2
50	Placebo	8KZM-KVM4	2	10	original	5	0	3
51	Neutral	G5MQ-43Y7	3	2	original	1	1	2
52	Neutral	J5G7-MUNE	3	6	correction_replacement	4	0	2

scoring order	condition	target id	planned session	trial position	source type	true target rank	top1 hit	speci
53	Campbell	RLA2-6WFM	3	10	original	2	0	2
54	Campbell	S7ZX-RAK2	3	4	original	3	0	2
55	Placebo	Q7MA-MHXY	2	2	original	2	0	3
56	Campbell	9PA6-TYLT	2	3	original	5	0	2
57	Neutral	MPEN-XAFC	3	3	original	2	0	3
58	Placebo	WHCS-R6CC	3	4	original	1	1	2
59	Campbell	SPY2-GRWE	1	9	original	5	0	2
60	Placebo	9HVR-79NR	1	10	original	2	0	2
61	Neutral	UFZA-FKVH	3	8	original	1	1	2
62	Neutral	77RZ-55NU	3	1	original	3	0	2
63	Campbell	P7WX-4BZH	2	6	correction_replacement	2	0	2
64	Campbell	3M4D-D6QK	3	6	original	4	0	3
65	Neutral	W4WC-SV3T	1	8	original	4	0	3

scoring order	condition	target id	planned session	trial position	source type	true target rank	top1 hit	speci
66	Campbell	K39X-PE6Y	1	2	original	2	0	2
67	Neutral	ZNMH-4DZW	2	6	original	3	0	1
68	Campbell	MG87-TP8T	1	3	original	2	0	3
69	Placebo	RLA2-6WFM	1	1	original	2	0	2
70	Placebo	22MX-UQCV	1	9	original	5	0	1
71	Neutral	S7ZX-RAK2	2	5	original	2	0	1
72	Neutral	9PA6-TYLT	1	9	original	2	0	1
73	Placebo	HFN9-DPRM	3	7	correction_replacement	3	0	2
74	Neutral	D2T2-HUYC	2	4	original	3	0	1
75	Neutral	R6XA-BAZH	1	3	original	1	1	3
76	Neutral	Q7MA-MHXY	1	5	original	1	1	2
77	Neutral	M3JW-WM39	3	5	original	4	0	1
78	Placebo	AF4D-NG43	3	10	original	5	0	1

scoring order	condition	target id	planned session	trial position	source type	true target rank	top1 hit	speci
79	Placebo	MPEN-XAFC	3	1	original	1	1	2
80	Campbell	SJCJ-RD7E	3	3	original	5	0	2
81	Placebo	77RZ-55NU	3	8	correction_replacement	4	0	2
82	Neutral	3M4D-D6QK	2	9	original	2	0	1
83	Campbell	P5NN-D5ET	3	2	original	3	0	2
84	Neutral	MG87-TP8T	3	4	original	5	0	1
85	Campbell	G5MQ-43Y7	1	4	original	1	1	0
86	Neutral	5HPZ-G2ZS	1	6	original	2	0	2
87	Neutral	CE9E-ZRN2	1	1	original	1	1	2
88	Placebo	J5G7-MUNE	2	3	original	3	0	2
89	Neutral	8KZM-KVM4	3	7	original	1	1	1
90	Campbell	HFN9-DPRM	2	9	original	3	0	2

Integrity

Scoring plan SHA-256:

394577b55616e111689efe386561d8d02768f0360f7a6cbc4445673a0518468f